Janux Therapeutics, Inc. Diluted Shares Outstanding (Weighted Average)
Janux Therapeutics, Inc. (JANX) reported Diluted Shares Outstanding (Weighted Average) of 62.94 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-06
- Janux Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 62.94M shares, a 1.67% increase year-over-year.
- Janux Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 62.67M shares, a 1.41% increase year-over-year.
- Janux Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 62.15M shares, a 9.31% increase year-over-year.
- Janux Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 62.02M shares, a 13.54% increase year-over-year.
- Janux Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 61.97M shares, a 15.28% increase from fiscal 2024.
- Janux Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 53.75M shares, a 22.12% increase from fiscal 2023.
- Janux Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 44.02M shares, a 6.14% increase from fiscal 2022.
- Janux Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2022 was 41.47M shares, a 76.24% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 62.94M shares 10-Q · filed 2026-08-06 | 62.80M shares 10-Q · filed 2026-08-06 | 62.58M shares derived: average of 3 quarters · filed 2026-08-06 | 62.44M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 62.67M shares 10-Q · filed 2026-05-07 | 62.41M shares derived: average of 2 quarters · filed 2026-05-07 | 62.28M shares derived: average of 3 quarters · filed 2026-05-07 | 62.18M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 62.15M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 62.09M shares derived: average of 2 quarters · filed 2026-02-26 | 62.02M shares derived: average of 3 quarters · filed 2026-08-06 | 61.97M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 62.02M shares 10-Q · filed 2025-11-06 | 61.96M shares derived: average of 2 quarters · filed 2026-08-06 | 61.91M shares 10-Q · filed 2025-11-06 | 60.64M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 61.90M shares 10-Q · filed 2026-08-06 | 61.85M shares 10-Q · filed 2026-08-06 | 60.18M shares derived: average of 3 quarters · filed 2026-08-06 | 58.79M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 61.79M shares 10-Q · filed 2026-05-07 | 59.32M shares derived: average of 2 quarters · filed 2026-05-07 | 57.76M shares derived: average of 3 quarters · filed 2026-05-07 | 56.93M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 56.85M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 55.74M shares derived: average of 2 quarters · filed 2026-02-26 | 55.31M shares derived: average of 3 quarters · filed 2026-02-26 | 53.75M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 54.63M shares 10-Q · filed 2025-11-06 | 54.54M shares derived: average of 2 quarters · filed 2025-11-06 | 52.72M shares 10-Q · filed 2025-11-06 | 51.21M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | 54.45M shares 10-Q · filed 2025-08-07 | 51.75M shares 10-Q · filed 2025-08-07 | 50.07M shares derived: average of 3 quarters · filed 2026-02-26 | 48.98M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | 49.05M shares 10-Q · filed 2025-05-08 | 47.88M shares derived: average of 2 quarters · filed 2026-02-26 | 47.16M shares derived: average of 3 quarters · filed 2026-02-26 | 45.83M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | 46.71M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 46.21M shares derived: average of 2 quarters · filed 2026-02-26 | 44.75M shares derived: average of 3 quarters · filed 2026-02-26 | 44.02M shares 10-K · filed 2026-02-26 |
| 2023-09-30 | 45.71M shares 10-Q · filed 2024-11-06 | 43.77M shares derived: average of 2 quarters · filed 2024-11-06 | 43.12M shares 10-Q · filed 2024-11-06 | 42.72M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | 41.84M shares 10-Q · filed 2024-08-07 | 41.80M shares 10-Q · filed 2024-08-07 | 41.73M shares derived: average of 3 quarters · filed 2025-02-27 | 41.68M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | 41.76M shares 10-Q · filed 2024-05-08 | 41.67M shares derived: average of 2 quarters · filed 2025-02-27 | 41.63M shares derived: average of 3 quarters · filed 2025-02-27 | 41.58M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | 41.59M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 41.56M shares derived: average of 2 quarters · filed 2025-02-27 | 41.52M shares derived: average of 3 quarters · filed 2025-02-27 | 41.47M shares 10-K · filed 2025-02-27 |
| 2022-09-30 | 41.53M shares 10-Q · filed 2023-11-07 | 41.49M shares derived: average of 2 quarters · filed 2023-11-07 | 41.43M shares 10-Q · filed 2023-11-07 | 41.42M shares derived: average of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | 41.45M shares 10-Q · filed 2023-08-08 | 41.38M shares 10-Q · filed 2023-08-08 | 41.39M shares derived: average of 3 quarters · filed 2023-08-08 | 41.33M shares derived: average of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | 41.32M shares 10-Q · filed 2023-05-09 | 41.36M shares derived: average of 2 quarters · filed 2023-05-09 | 41.28M shares derived: average of 3 quarters · filed 2023-05-09 | 33.47M shares derived: average of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | 41.40M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | 41.27M shares derived: average of 2 quarters · filed 2023-03-10 | 30.86M shares derived: average of 3 quarters · filed 2023-03-10 | 23.53M shares 10-K · filed 2023-03-10 |
| 2021-09-30 | 41.13M shares 10-Q · filed 2022-11-10 | 25.58M shares derived: average of 2 quarters · filed 2022-11-10 | 17.57M shares 10-Q · filed 2022-11-10 | |
| 2021-06-30 | 10.03M shares 10-Q · filed 2022-08-09 | 5.60M shares 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |